Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX1 Vaccine in Healthy Donors for HPV 16-Associated Malignancy
NCT06508138Phase 1Enrolling by invitation
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PVX1 in malignant neoplasm (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Adverse Events at 3 months. Started Oct 2023; status: enrolling by invitation.
02
Drugs
PVX1
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT06508138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508138.